Streetbeat News

Price Targets

GPCR

Cantor Fitzgerald analyst Prakhar Agrawal has reiterated an Overweight rating on Structure Therapeutics (NASDAQ:GPCR) and maintained a $65 price target.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 12:22 pm

CELC

Stifel analyst Bradley Canino maintains a Buy rating on Celcuity (NASDAQ:CELC) but lowers the price target from $40 to $39.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 12:16 pm

PYCR

Stifel analyst Brad Reback maintains a Buy rating on Paycor HCM (NASDAQ:PYCR) but lowers the price target from $22 to $19.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 12:15 pm

LITE

Lumentum Holdings shares are trading higher after the company reported better-than-expected Q4 financial results and issued Q1 revenue guidance above estimates. Additionally, Rosenblatt and Needham raised their respective price targets on the stock.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 12:15 pm

PARA

JP Morgan analyst Philip Cusick maintains an Underweight rating on Paramount Global (NASDAQ:PARA) and lowers the price target from $12 to $11.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 12:13 pm

ALL

CAH

CSCO

DELL

HOOD

IPSC

LITE

MDT

PGR

SNOW

Top Wall Street analysts have updated their outlooks on several major stocks. Notable changes include price target adjustments and rating changes for Lumentum Holdings, The Progressive Corporation, Century Therapeutics, Snowflake Inc., Cisco Systems, The Allstate Corporation, Medtronic plc, Dell Technologies, Cardinal Health, and Robinhood Markets.

Portfolio Pulse from Avi Kapoor

August 15, 2024 | 12:11 pm

IGMS

JP Morgan analyst Eric Joseph maintains a Neutral rating on IGM Biosciences (NASDAQ:IGMS) and raises the price target from $11 to $12.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 12:11 pm

KE

Sidoti & Co. analyst Anja Soderstrom has downgraded Kimball Electronics (NASDAQ:KE) from Buy to Neutral and set a price target of $19.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 12:10 pm

MRNA

JP Morgan analyst Jessica Fye maintains a Neutral rating on Moderna (NASDAQ:MRNA) but lowers the price target from $96 to $88.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 12:09 pm

DELL

Dell Technologies shares are trading higher after JP Morgan maintained an Overweight rating on the stock and raised its price target from $155 to $160.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 12:07 pm